Nasdaq

Kernel's Revolutionary Neuroimaging Technology, Flow1, Validated in Published Feasibility Study on Measuring Psychedelic Effects

LOS ANGELES--(BUSINESS WIRE)-- Kernel, a leader in non-invasive neuroimaging, announces the publication of their study "Measuring acute effects of subanesthetic ketamine on cerebrovascular ...
Business Wire

Kernel Launches Observational Study Using Flow2 Neuroimaging Technology to Identify Biomarkers of Depression Treatment Response

LOS ANGELES--(BUSINESS WIRE)--Kernel, an innovator in non-invasive neuroimaging technology, announces the first patient has been measured in an observational study of depression treatments using ...
Business Wire

Cybin and Kernel Announce Results from Kernel Flow ® Piloting of Feasibility Study Measuring Ketamine’s Effects on the Brain

- Results to be presented at PSYCH Symposium taking place in London on May 11, 2022 - LOS ANGELES & TORONTO--(BUSINESS WIRE)--Kernel, a leader in non-invasive neuroimaging, and Cybin Inc. (NEO:CYBN) ...
Healio

Cybin, Kernel announce positive results from neuroimaging technology pilot study

Please provide your email address to receive an email when new articles are posted on . Neurotechnology firm Kernel and biopharmaceutical company Cybin announced promising pilot results from a ...